Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Amen. Awesome prayer.
Pound sand.
Pumping in bold, throwing around BIG IF's is concerning. Will check back after phase1 starts.
Leo's leadership is genius. Corporate update anyday now.
Had my eye on this one for a few weeks but missed the June ride. Nice buy at this level. Waiting for my other two picks to also shoot past Pluto. Good luck.
Had my eye on this one for a few weeks but missed the June ride. Nice buy at this level. Waiting for my other two picks to also shoot past Pluto. Good luck.
Or like the CTIX story rising on a rocket...
By the time we figure it out we will be at $4.00. It's all good.
Got Cellceutix on the other line. Said Dr who..
My research shows the company was previously named Nuvilex. Why the name change? Phase1 trial planned end of third quarter.
As we wait on the FDA outcome we can be very optimistic that FDA phase3 approval will happen with QIDP designation. Just review ECCMID 2015 slides 19-21 and be assured. Brilacidin was found safe and effective in two phase 2 studies. This is my opinion with evidence.
Just comparing any American DR or CEO to that horrible North Korean regime should give readers pause.
Friday is a banking holiday. Hopefully fireworks in 3 weeks.
hehe mom knew best when she said "go look it up for yourself". Really exciting gem with a huge upswing potential.
Thanks.
Find complete Trial design clinicaltrials.gov
https://clinicaltrials.gov/ct2/show/NCT02244541?term=anavex&rank=1
The primary objective of this Phase 2a study is to evaluate the maximal tolerated dose of ANAVEX2-73 in patients with AD in a repeated-dose administration scheme, with the secondary objectives being to explore the relationship between dosing regimen and pharmacodynamics efficacy outcomes and to evaluate the bioavailability of the oral form used and to explore the relationship of ANAVEX2-73 as add-on therapy to AD standard of care.
Drano I like this part: The CEO announced “With its adaptive design, the aim of this trial is to objectively measure all possible effects of the drug in patients, which serves to optimally design and reduce the risk for future pivotal trials". To me Adaptive design means it could easily segway straight into a phase3 by this fall without the delay that comes with setting up a new trial design. What do you think?
Yes, IMO they are seeing great early efficacy in the phase2a clinical trial data and made the decision hold it for the Alzheimer’s Association International Conference (AAIC) in Washington DC. With this poster having meaningful data as it sounds to be so far there should be a lot of eyes on Anavex at the conference.
Just one disappointment after another..
I agree, the month is over in two days. As we know from last update Leo reported the meeting would take place the end of June and he will report phase3 news in a corporate update at the middle to end of July. Were getting down to the wire.
B-OM enrollment began four weeks ago. Oral Rinse used 3 times daily for 7 weeks. First patients should complete dosing around last week of July. Pray B-OM totally alleviates these poor peoples OM suffering. Pictures of the disease are ghastly.
Thanks for the response and CRO link. Will check back periodically.
Have phase1 trial locations been selected? Where will the trial be tracked? Searched pmcb on clinicaltrials.gov but retrieved no search results. Thanks in advance.
Trial sites? How will the testing be tracked? Thanks.
woohoo take that Ben Sharvy..
Just alleviating some of the debilitating symptoms should get it to approval. The method now is ice chips.
I believe you are right that Leo thought with the promising early Brilacidin ABSSSI data the share price would fall into line with uplisting. Now after FDA meeting this month Brilacidin will probably still be the catalyst hopefully next month.
Company Spotlight
3 Innovators Leading the next breakthroughs in Technology.
http://ir.baystreet.ca/article.aspx?id=139&1434607733
New Approach to Alzheimer’s Disease: (Anavex Life Sciences: AVXL)
Dr. Christopher Missling is the CEO and President of Anavex. The biotech company is developing interesting and novel compounds to treat Alzheimer’s disease, CNS diseases and conditions that are of significant unmet medical need. Two decades of health care experience, a MS and PhD from the University of Munich in Chemistry and an MBA from Northwestern University Kellogg School of Management underscore Dr. Missling’s science and business acumen.
Missling has amassed a rich pipeline at Anavex, advancing two drug candidates to mid-stage trials. The company is hoping to reduce development risk with its lead drug candidate, Anavex Plus, for Alzheimer’s because it combines Anavex 2-73 with donepezil. Anavex Plus is unique in targeting multiple AD pathways simultaneously at different levels of the disease stage. The company believes Anavex Plus could have commercial appeal due to donepezil, the world’s best selling Alzheimer’s drug marketed by Japan’s Eisai (ESALY) and Pfizer (PFE) as Aricept®, losing patent protection in 2010. Dr. Missling’s resume includes serving as CFO of Curis (CRIS) and CFO at Immunogen (IMGN). He also was in charge of financial planning on all aspects of financial strategy and M&A during his time at Aventis, which eventually became part of what is now Sanofi (SNY) subsequent to a $64 billion merger in 2004.
Durable Alzheimer’s treatments have eluded drug makers for years. The value of an effective therapy was evidenced in the massive initial public offering last week of Axovant Sciences Ltd (AXON), a company with no marketed products, but a heralded Alzheimer’s drug ready to enter a Phase 3 trial.
Conclusion
In today’s environment, successful companies must be able to quickly adapt to changing markets and new technology. These industry leaders have been able to create promising businesses that are capitalizing on new technology, positioning their companies as forerunners in their perspective markets. This should lead to exponential growth, making them companies to watch.
My thoughts exactly. I'm excited to hear outcome of FDA meeting and when Phase3 commences. Should be a great summer.
My thoughts exactly.
Form 8-K out today.
17-Jun-2015
Change in Directors or Principal Officers
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Effective June 15, 2015 (the "Effective Date" ), the board of directors (the "Board" ) of Anavex Life Sciences Corp., a Nevada corporation (the "Company" ), appointed Steffen Thomas, PhD, to serve as a member of the Board until his successor is duly elected, qualified and seated or until his earlier resignation or removal.
In addition to being a member of the Board, it is anticipated that Dr. Thomas will serve on the Audit Committee, effective as of the Effective Date. As compensation for his services, the Company granted Dr. Thomas options to purchase two hundred thousand (200,000) shares of common stock in the Company, said options to vest annually over a three year period commencing on the first anniversary of the Effective Date.
The Company has not entered into any transactions with Dr. Thomas that would require disclosure pursuant to Item 404(a) of Regulation S-K under the Exchange Act of 1934, as amended.
I agree Brillacidin FDA phase 3 approval will be huge for CTIX and really further validate B-OM as well as the other trials Brillacidin would be used in.
No, the truth is Brillacidin was never delayed. Before formal meeting took place FDA asked for a complete patient study workup which took more time. Perhaps Leo got ahead of himself do to his high confidence. A FDA delay sounds much scarier though huh.
Uplist is a work in progress. Even with the delay, indications show this stock will soon moon shot with or without uplist. Uplist will soon follow I might add.
Nice retrace rally. Expecting more positive trial news soon.
Thanks! btw go pound sand.
There are no guarantees. Didn't you look over the last 10-Q.
Prurisol effective against psoriasis so in theory it could possibly work clearing other Autoimmune diseases.
I have adblockplus for chrome running in the back ground. Works like a charm shooting down ads and popups. adblockplus.org
I believe as in the case of CTIX today that the upcoming developing catalysts will remedy low share price without a need of R/S. We have the goods why give up 50 or 75% of your shares to arrive at the same pps a little while down the road. We are only down by some .40cents to get on the Nasdaq CM. Brillacidin catalyst alone could do this.
Sounds like sage advice.